|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||22.70 - 22.70|
|52-week range||22.70 - 22.70|
|Beta (5Y monthly)||1.23|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the following virtual conferences in March 2021:
We feel now is a pretty good time to analyse UroGen Pharma Ltd.'s ( NASDAQ:URGN ) business as it appears the company...
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC). UroGen’s approach involves the local delivery of potent immunomodulators (UGN-201, a TLR 7/8 agonist and UGN-301, an anti-CTLA-4 antibody). UGN-301, an immune checkpoint inhibitor, is delivered using UroGen’s proprietary RTGel™ platform to increase dwell time, which has been shown to significantly improve the effectiveness of intravesical therapy.